Filing Details
- Accession Number:
- 0000897069-24-000229
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-31 16:37:40
- Reporting Period:
- 2024-01-30
- Accepted Time:
- 2024-01-31 16:37:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1533743 | Processa Pharmaceuticals Inc. | PCSA | Pharmaceutical Preparations (2834) | 451539785 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1638744 | K George Ng | C/O Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover MD 21076 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-01-30 | 10,000 | $2.70 | 20,000 | No | 4 | P | Indirect | By Family Trust |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By Family Trust |
Footnotes
- Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- Reflects that shares previously reported as directly held by the reporting person were held in a trust.